• Integrative biomarker-based prevention of cardiovascular and metabolic diseases, personalized therapy, and identification of drug targets

The pilot project aims to create new techniques and methods of personalized monitoring, diagnostic and treatment, aiming to promote implementation of the latest scientific discoveries and modern technologies into a clinical practice to improve survival and quality of life of Latvian population.

achievements of the Latvian Biomedical Research and Study

• Antimicrobial resistance ecosystem in hospitals and environmental objects

The main task of this pilot project is to introduce the "One Health" principle in research, collect information on the spread of AMR, and develop solutions for controlling AMR and reducing environmental pollution.

• Discovery of new anti-infective medicines

The pilot project is designed to identify and formulate selective inhibitors of SARS-CoV-2 mRNA cap methyltransferases, namely nsp14 and nsp16, with the aim of developing lead compounds for a broad-spectrum antiviral drug.

• Discovery of a new approach towards anti-AD medicines and identification of MS biomarkers

The pilot project has two main objectives: to generate vaccine candidates against Alzheimer's disease (AD) and to develop a statistical model for predicting relapsing and disability in patients with relapsing-remitting MS (RRMS).

• Development of local drug delivery systems based on personalized 3D biomaterial implants

The pilot project aims to address the evident clinical need for innovative therapeutic approaches to enhance bone cancer treatment and local tissue regeneration post-surgery. The project's goal is to establish a methodology for the preparation of patient-specific implants applicable in reconstructive surgery. 3D biomaterial scaffolds will be modified to function as local drug delivery systems, facilitating prolonged and controlled release of drugs.

• Development of new cancer diagnostics and treatment methods

The pilot project aims to contribute to the creation of high-value products by introducing conceptually innovative technologies for cancer detection and prognosis. It will offer new biomarkers and testing platforms for anti-cancer drug discovery. Additionally, the project seeks to advance knowledge in cancer biology, drug design, mitochondrial functions, and intercellular communication within the tumor microenvironment.

• Implementation of big data-guided precision medicine solutions

The pilot project aims to create a universally adaptable IT tool for calculating polygenic risk specific to the Latvian population. It will assess the tool's performance in determining the risk of common multifactorial diseases and develop recommendations for its integration into existing disease prevention and treatment programs in Latvia.